TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05997017: Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Sponsor: Aadi Bioscience, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 29 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,755,600

Rescue Site Savings

+$1,155,000

Unlock Full NCT05997017 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05997017 Rescue Dossier →